Introduction
Mitomycin C is a chemotherapy medication used intravesically to treat non-muscle invasive bladder cancer (NMIBC). By targeting and destroying cancer cells, Mitomycin C helps reduce the risk of recurrence and progression, making it a valuable option in bladder cancer management.
Purpose
- Treats non-muscle invasive bladder cancer, particularly following transurethral resection of bladder tumor (TURBT).
- Reduces the risk of cancer recurrence and progression.
- Provides an alternative or adjunct to BCG therapy in specific cases.
How It Works
Mitomycin C is an alkylating agent that prevents cancer cells from dividing and growing. When instilled into the bladder, it directly targets the lining, delivering high concentrations of the drug to the cancer site with minimal systemic exposure.
Usage
- Administered directly into the bladder through a catheter (intravesical therapy), typically as a single dose immediately after TURBT or in weekly sessions.
- Patients are advised to hold the medication in the bladder for 1-2 hours before voiding.
- Treatment schedules may vary based on individual patient needs and cancer characteristics.
Considerations
- Common side effects include bladder irritation, painful urination, and mild urinary frequency.
- Rare but serious side effects include allergic reactions or bladder wall inflammation (cystitis).
- Patients are advised to avoid caffeine and limit fluid intake on treatment days to reduce discomfort.
At Crossroads Urology
At Crossroads Urology, we incorporate Mitomycin C therapy into tailored bladder cancer treatment plans. Our providers prioritize patient safety and comfort while maximizing the effectiveness of this proven chemotherapy.
Conclusion
Mitomycin C is a powerful intravesical chemotherapy for managing non-muscle invasive bladder cancer, helping patients achieve excellent outcomes with minimal systemic side effects. Contact Crossroads Urology today to learn more about this treatment and how it can benefit you.
